Aurobindo Pharma is a global generics manufacturer that turns chemistry into affordable medicine - it makes the active ingredients (the molecules that treat the disease) and the finished pills, injectables and inhalers that patients take, then sells them in over 150 countries. Founded in 1986 with a single factory in Pondicherry, it grew into India’s second-largest listed pharma company by revenue through a series of acquisitions - starting with a UK generics business in 2006 and a US manufacturing plant in 2007 - that gave it direct access to the world’s two biggest drug markets. The recurring approach is vertical integration: the company runs every major business as a separate entity, but feeds them from its own API factories, so it controls the supply chain from raw material to pharmacy shelf.
Business segments
Four engines at different stages - a US generics cash cow that fills one in every ten American prescriptions, a European platform that just crossed a billion euros, an API backbone that supplies both the group and rivals, and a cluster of next-generation bets in injectables, biosimilars and biologics manufacturing - each built on the chemistry and regulatory know-how of the one before.
1. US Formulations: the prescription-volume leader in the world’s toughest generics market
Aurobindo is the largest generics company in the United States by prescriptions dispensed, with one in every ten generic oral-solid prescriptions carrying its label - a volume-driven business where breadth of portfolio and manufacturing scale absorb the constant price erosion.
- Sheer portfolio breadth - the company actively markets more than 236 oral solid products and 81 injectables, and ranks among the top four players in over 75% of its oral portfolio and 65% of its injectables in the US market, so no single product loss can destabilise the business.
- The ANDA factory - with 888 cumulative filings and 728 final approvals as of March 2026, the company has one of the industry’s deepest pipelines of abbreviated new drug applications, spanning therapies from central nervous system drugs to oncology, with a combined addressable market of roughly $192 billion.
- Bought, not just built - the June 2026 acquisition of Lannett Company added a 425,000-square-foot plant in Indiana that can produce about 3.6 billion tablets a year, plus a portfolio of non-opioid controlled substances (mainly ADHD treatments) and a growing contract-manufacturing business, for an enterprise value of $250 million.
- US manufacturing on the ground - plants in Dayton (New Jersey) and Raleigh (North Carolina) now produce oral solids and topicals domestically, with Raleigh expected to add transdermal and respiratory products, reducing reliance on India-based supply for the US market.
- A branded oncology sidecar - subsidiary Acrotech Biopharma markets seven injectable oncology products, including the recently approved Ryzneuta for chemotherapy-induced neutropenia, giving the company a small but direct presence in the higher-margin branded space.
2. Europe Formulations: a billion-euro pharmacy-and-hospital network
The European business reached €1 billion in annual revenue in FY26, ranking among the top ten generics companies in eight countries - including four of the EU’s five largest - by supplying pharmacies, hospitals and government tenders largely from its own Indian factories.
- In-house supply as the margin lever - over 73% of the products sold in Europe (by volume) are manufactured in Aurobindo’s own plants in India, so the company captures the manufacturing margin rather than paying a third-party supplier.
- A distributor deal that opens five markets - a partnership with Phoenix, Europe’s largest pharmaceutical distributor, covers France, the UK, Italy, the Netherlands and Belgium, giving the company shelf access without building its own logistics in every country.
- Regulatory mass - as of March 2026 the company had 4,344 formulation filings and 2,153 API filings across Europe, a dossier bank that lets it launch products quickly once patents expire.
- Local testing and now local making - a batch-testing facility in Malta (supplemented by the acquired Ace Laboratories in the UK) handles quality release for oral and injectable products, while a newly incorporated French subsidiary, Arrow Pharma Production, signals a move toward manufacturing generic formulations inside Europe itself.
3. Active Pharmaceutical Ingredients: the factory that feeds the group
The API business is the foundation of Aurobindo’s vertical-integration model - it manufactures 19,000 metric tonnes of active ingredients annually, supplies roughly half of the company’s own formulation needs, and sells the rest to innovator and large generic companies worldwide.
- Two chemistries under one roof - the company is one of the few global API makers with large-scale presence in both beta-lactams (penicillins, cephalosporins, penems) and non-beta-lactams, with beta-lactams contributing 70% of API sales.
- Hived off to focus - the entire API business was transferred to a dedicated subsidiary, Apitoria Pharma, in October 2023 and given its own CEO, so it can pursue external customers aggressively without being treated as an internal supplier.
- Multiple plants, multiple stages - seven Apitoria-named facilities plus dedicated units for peptides, Penicillin-G, 6-APA and paracetamol give the company the flexibility to sell at intermediate or finished-API stage depending on where prices are best.
- Regulatory reach - 322 API filings in the US, 2,153 in Europe and 1,769 in other markets mean the API business can sell into virtually any regulated market where its formulation customers operate.
4. Specialty, injectables and next-generation bets: the future pipeline
A cluster of subsidiaries - Eugia for complex injectables, CuraTeQ for biosimilars, TheraNym for biologics contract manufacturing, and a pipeline of respiratory, dermatology and peptide products - represents the company’s push beyond oral generics into high-barrier therapies where competition is scarcer and margins are structurally higher.
- Eugia’s injectable engine - with five manufacturing plants and 178 ANDA filings (143 approved), Eugia generated $513 million in global revenue in FY26 from complex injectables, oncology and hormones, including drug-device combinations like auto-injectors and long-acting depot products.
- Biosimilars with a 2030 horizon - CuraTeQ has four products already launched in the UK (and approved in the EU and Canada), a 15-product pipeline targeting a global market of over $50 billion as blockbuster biologics lose patent protection, and a marketing deal with STADA for France and Germany.
- The MSD anchor - TheraNym’s biologics contract-manufacturing facility near Hyderabad has Merck Sharp & Dohme as a ten-year anchor customer, with a second 60,000-litre unit now being built under an expanded agreement, taking total mammalian-cell capacity across three product schedules to about 120,000 litres - the largest CMO space in India.
- Complex generics beyond injectables - the pipeline includes 22 respiratory products (inhalers and nasal sprays), 59 dermatology products, 10 transdermal patches, and peptide APIs including GLP-1 receptor agonists, all areas where manufacturing difficulty limits the number of competitors.
- Backward integration into the raw material - the Penicillin-G plant in Kakinada (15,000 tonnes annual capacity) and the 6-APA plant (3,600 tonnes) were commercialised in March 2024 under India’s PLI scheme, reducing dependence on Chinese imports and, by converting Pen-G at the liquid stage, cutting costs for the formulations business.
Group structure and partners
Aurobindo operates through more than 90 subsidiaries, with every major business line housed in its own dedicated company - a structure management describes as treating each business as a separate entity.
- The standalone engines - Eugia Pharma runs specialty injectables, CuraTeQ Biologics runs biosimilars, TheraNym runs biologics contract manufacturing, Apitoria Pharma runs APIs, and Auropharm (formerly Auro Pharma) now consolidates the entire domestic branded-generics business after a July 2026 transfer.
- The US and Europe vehicles - Aurobindo Pharma USA manages the American generics business (and completed the Lannett acquisition in June 2026), while European operations run through country-specific subsidiaries including Milpharm in the UK, Arrow Generiques in France, Puren Pharma in Germany, and Generis in Portugal.
- Anchor partnerships - MSD is the ten-year anchor customer for TheraNym’s CMO business, STADA markets two CuraTeQ biosimilars in France and Germany, and Phoenix distributes products across five European markets.
- Clean-up and consolidation - the company divested its Natrol dietary-supplement business for $550 million in FY21, exited the Czech Republic and scaled down Romania, terminated a vaccine license with Hilleman Laboratories, and is merging Auro Vaccines into CuraTeQ to streamline the biologics entity.